Jiangsu Jibeier Pharmaceutical (688566)2024-05-10 11:20Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes not paying cash dividends or issuing bonus shares [1][2][3] - The board has proposed to authorize the formulation of a mid-year dividend plan for 2024, which will be reviewed at the 2023 annual shareholders' meeting [4] - The company emphasizes investor returns and aims to balance long-term development with reasonable returns to investors [4] Group 2: Product Development and Clinical Trials - The company has introduced a new diabetes medication, JJH202301, which has shown promising results in preliminary pharmacokinetic studies, indicating a significant extension of the drug's half-life and reduced metabolite production [2][3] - The anti-cancer drug JJH201601 has received approval for clinical trials and is currently in Phase I studies, with multiple dosage groups already enrolled [3][5] - The company has patented multiple formulations of its existing drug, Likujun, to enhance product quality and clinical efficacy, thereby reducing the risk of imitation [3][5] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is positioned as a leading product in this category [5][6] - Sales data indicates uneven development across different regions, suggesting a considerable untapped market nationally [5] - The application of Likujun in oncology has been recognized in clinical guidelines, further enhancing its market prospects [5][6]